Pain Clinical Trial
Official title:
A Prospective Observational Study to Evaluate the Safety of COVID-19 Vaccination in Children and Adolescents
NCT number | NCT05157191 |
Other study ID # | Pro00110056 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | April 6, 2022 |
Est. completion date | October 27, 2023 |
Verified date | December 2023 |
Source | Duke University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This is a prospective, observational study. During the study, children and adolescents (ages ≥ 5 to < 16) will be followed post administration of mRNA COVID-19 vaccines. Injection site (local), systemic reaction, and unsolicited adverse event data will be assessed on vaccination day and during the 7 days following each vaccination using either identical web-based or paper diaries, depending on study participant preference. At Duke University, Cincinnati's Children Hospital, and Kaiser Permanente Northern California, serum samples will be collected for optional assessment of antibody titers to COVID-19. Each participant who opts in will have baseline (within 3 days of vaccination) serologies obtained and immunogenicity assessment at 28 (+7) days after each dose. All participants will be followed for 180 days after dose 2 for serious adverse events and adverse events of special interest.
Status | Completed |
Enrollment | 299 |
Est. completion date | October 27, 2023 |
Est. primary completion date | May 25, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 5 Years to 15 Years |
Eligibility | Inclusion Criteria: 1. Children = 5 years to < 16 years of age 2. Receiving first dose or a booster dose of a U.S authorized or approved and recommended COVID-19 vaccine per standard of care 3. Parent/legal authorized representative (LAR) willing to provide written informed consent per local IRB requirements 4. Participant willing to provide assent per local IRB requirements 5. Intention of being available for entire study period and complete all relevant study procedures, including follow-up phone calls 6. English or Spanish literate. Exclusion Criteria: 1. Current or planned participation in any clinical trial with an investigational product during the study period.* - Per protocol, co-enrollment in observational or behavioral intervention studies are permitted at any time. An investigational product or behavioral intervention permitted at any time. An investigational product may be permitted for therapy of an illness condition that occurs during the study period (e.g., COVID-19 illness) 2. Any condition, which, in the opinion of the investigators, may pose a health risk to the subject or interfere with the evaluation of the study objectives. 3. Anyone who is a relative of any research study personnel or is an employee supervised by study staff. |
Country | Name | City | State |
---|---|---|---|
United States | Centers for Disease Control and Prevention | Atlanta | Georgia |
United States | Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio |
United States | Duke University | Durham | North Carolina |
United States | Columbia University | New York | New York |
United States | Kaiser Permanente Northern California | Oakland | California |
Lead Sponsor | Collaborator |
---|---|
Duke University | Centers for Disease Control and Prevention, Children's Hospital Medical Center, Cincinnati, Columbia University, Kaiser Permanente |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants with defined local or systemic reactogenicity events after each dose of COVID-19 vaccine | Tables summarizing each solicited local and systemic reactogenicity event by maximum classification (none, mild, moderate, and severe), as well as by moderate or severe | Up to 7 days post-vaccination | |
Primary | Number of participants with at least one severe (Grade 3) solicited local or systemic reactogenicity event after each dose of COVID-19 vaccine | Tables summarizing each severe (Grade 3) solicited local and systemic reactogenicity event | Up to 7 days post-vaccination | |
Primary | Number of participants with at least one moderate-to-severe (Grade 2-3) solicited local or systemic reactogenicity event after each dose of COVID-19 vaccine | Tables summarizing each moderate-to-severe (Grade 2-3) solicited local and systemic reactogenicity event | Up to 7 days post-vaccination | |
Primary | Number of participants with an unsolicited adverse events after each dose of COVID-19 vaccine | The number and percent and descriptions of unsolicited adverse events observed | Up to 7 days post-vaccination | |
Primary | Number of participants with an adverse event of special interest | The number and percent of individuals with an adverse event of special interest after dose 2 of COVID-19 vaccine | Up to 29 days post-vaccination | |
Primary | The number and percent of participants with at least one serious adverse event after dose 2 of COVID-19 vaccine | The number and percent of serious adverse events observed and description of each event | Up to 29 days post-vaccination | |
Secondary | Number of participants with defined local or systemic reactogenicity events after receiving other routinely recommended vaccines with each dose of COVID-19 vaccine | Tables summarizing each solicited local and systemic reactogenicity event by maximum classification (none, mild, moderate, and severe), as well as by moderate or severe | Up to 7 days post-vaccination | |
Secondary | Number of participants with defined local or systemic reactogenicity events after receiving each dose of COVID-19 vaccine without other vaccines | Tables summarizing each solicited local and systemic reactogenicity event by maximum classification (none, mild, moderate, and severe), as well as by moderate or severe | Up to 7 days post-vaccination | |
Secondary | Number of participants with at least one severe (Grade 3) solicited local or systemic reactogenicity event after other routinely recommended vaccines with each dose of COVID-19 vaccine | Tables summarizing each moderate to severe (Grade 2-3) solicited local and systemic reactogenicity event | Up to 7 days post-vaccination | |
Secondary | Number of participants with at least one severe (Grade 3) solicited local or systemic reactogenicity event after receiving COVID-19 vaccine without receiving other vaccines | Tables summarizing each severe (Grade 3) solicited local and systemic reactogenicity event | Up to 7 days post-vaccination | |
Secondary | Number of participants with at least one moderate-to-severe (Grade 2-3) solicited local or systemic reactogenicity event after receiving other routinely recommended vaccines with each dose of COVID-19 vaccine | Tables summarizing each moderate-to-severe (Grade 2-3) solicited local and systemic reactogenicity event | Up to 7 days post-vaccination | |
Secondary | Number of participants with at least one moderate-to-severe (Grade 2-3) solicited local or systemic reactogenicity event after receiving COVID-19 vaccine without receiving other vaccines | Tables summarizing each moderate-to-severe (Grade 2-3) solicited local and systemic reactogenicity event | Up to 7 days post-vaccination | |
Secondary | Number of participants with an unsolicited adverse events after receiving other routinely recommended vaccines with each dose of COVID-19 vaccine | The number and percent and descriptions of unsolicited adverse events observed | Up to 7 days post-vaccination | |
Secondary | Number of participants with an unsolicited adverse events after receiving other routinely recommended vaccines with each dose of COVID-19 vaccine without receiving other vaccines | The number and percent and descriptions of unsolicited adverse events observed | Up to 7 days post-vaccination | |
Secondary | Number of participants with an adverse event of special interest who received other routinely recommended vaccines with each dose of COVID-19 vaccine | The number and percent of individuals who had at least one adverse event of special interest | Up to 29 days post-vaccination | |
Secondary | Number of participants with an adverse event of special interest who received other routinely recommended vaccines with each dose of COVID-19 vaccine without receiving other vaccines | The number and percent of individuals who had at least one adverse event of special interest | Up to 29 days post-vaccination | |
Secondary | The number and percent of participants with at least one serious adverse event who received other routinely recommended vaccines after dose 2 of COVID-19 vaccine | The number and percent of serious adverse events observed and description of each event | Up to 29 days post-vaccination | |
Secondary | The number and percent of participants with at least one serious adverse event who received other routinely recommended vaccines after dose 2 of COVID-19 vaccine without receiving other vaccines | The number and percent of serious adverse events observed and description of each event | Up to 29 days post-vaccination |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05559255 -
Changes in Pain, Spasticity, and Quality of Life After Use of Counterstrain Treatment in Individuals With SCI
|
N/A | |
Completed |
NCT04748367 -
Leveraging on Immersive Virtual Reality to Reduce Pain and Anxiety in Children During Immunization in Primary Care
|
N/A | |
Terminated |
NCT04356352 -
Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain
|
Phase 2/Phase 3 | |
Completed |
NCT05057988 -
Virtual Empowered Relief for Chronic Pain
|
N/A | |
Completed |
NCT04466111 -
Observational, Post Market Study in Treating Chronic Upper Extremity Limb Pain
|
||
Recruiting |
NCT06206252 -
Can Medical Cannabis Affect Opioid Use?
|
||
Completed |
NCT05868122 -
A Study to Evaluate a Fixed Combination of Acetaminophen/Naproxen Sodium in Acute Postoperative Pain Following Bunionectomy
|
Phase 3 | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Completed |
NCT03273114 -
Cognitive Functional Therapy (CFT) Compared With Core Training Exercise and Manual Therapy (CORE-MT) in Patients With Chronic Low Back Pain
|
N/A | |
Enrolling by invitation |
NCT06087432 -
Is PNF Application Effective on Temporomandibular Dysfunction
|
N/A | |
Completed |
NCT05508594 -
Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001
|
Phase 2/Phase 3 | |
Recruiting |
NCT03646955 -
Partial Breast Versus no Irradiation for Women With Early Breast Cancer
|
N/A | |
Active, not recruiting |
NCT03472300 -
Prevalence of Self-disclosed Knee Trouble and Use of Treatments Among Elderly Individuals
|
||
Completed |
NCT03678168 -
A Comparison Between Conventional Throat Packs and Pharyngeal Placement of Tampons in Rhinology Surgeries
|
N/A | |
Completed |
NCT03286543 -
Electrical Stimulation for the Treatment of Pain Following Total Knee Arthroplasty Using the SPRINT Beta System
|
N/A | |
Completed |
NCT03931772 -
Online Automated Self-Hypnosis Program
|
N/A | |
Completed |
NCT02913027 -
Can We Improve the Comfort of Pelvic Exams?
|
N/A | |
Terminated |
NCT02181387 -
Acetaminophen Use in Labor - Does Use of Acetaminophen Reduce Neuraxial Analgesic Drug Requirement During Labor?
|
Phase 4 | |
Recruiting |
NCT06032559 -
Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment
|
Phase 3 | |
Active, not recruiting |
NCT03613155 -
Assessment of Anxiety in Patients Treated by SMUR Toulouse and Receiving MEOPA as Part of Their Care
|